Mitochondrial dysfunction in epilepsy

Seminars in Pediatric Neurology

Volumn 20, Issue 3, 2013, Pages 176-187

  Khurana, Divya S ^a   Valencia, Ignacio ^a   Goldenthal, Michael J ^a   Legido, Agustín ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIOXIDANT; CARBAMAZEPINE; MITOCHONDRIAL DNA; PHENOBARBITAL; PHENYTOIN; REACTIVE OXYGEN METABOLITE; VALPROIC ACID;

ACUTE LIVER FAILURE; ARTICLE; CELL ENERGY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; EPILEPSY; EPILEPTOGENESIS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; KETOGENIC DIET; LIVER TOXICITY; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RESPIRATORY CHAIN; SEIZURE;

ANTICONVULSANTS; DNA, MITOCHONDRIAL; EPILEPSY; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84890138632     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2013.10.001     Document Type: Article

References (85)

1. Sack G.H. Introduction to the mini-review series on mitochondrial matters in epilepsy. J Bioenerg Biomembr 2010, 42:441-442.
2. Kothare S.V., Khurana D.S., Madsen J., et al. Epilepsy. Clinical Pediatric Neurosciences for Primary Care 2009, 267-301. American Academy of Pediatrics, Elk Grove Village. A. Legido, J.H. Piatt (Eds.).
3. Zsurka G., Kunz W.S. Mitochondrial dysfunction in neurological disorders with epileptic phenotypes. J Bioenerg Biomembr 2010, 42:443-448.
4. Bindoff L.A., Engelsen B.A. Mitochondrial diseases and epilepsy. Epilepsia 2012, 53(suppl 4):92-97.
5. Chen S.D., Chang A.Y., Chuang Y.C. The potential role of mitochondrial dysfunction in seizure-associated cell death in the hippocampus and epileptogenesis. J Bioenerg Biomembr 2010, 42:461-465.
6. Molinari F. Mitochondria and neonatal epileptic encephalopathies with suppression burst. J Bioenerg Biomembr 2010, 42:467-471.
7. Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol 2012, 54:397-406.
8. Finsterer J., Mahjoub S.Z. Mitochondrial epilepsy in pediatric and adult patients. Acta Neurol Scand 2013, 128:141-152.
9. Kang H.C., Lee Y.M., Kim H.D. Mitochondrial disease and epilepsy. Brain Dev 2013, 35:757-761.
10. Shoffner J.M., Lott M.T., Lezza A.M., et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA (Lys) mutation. Cell 1990, 61:931-937.
11. Khurana D.S., Salganicoff L., Melvin J.J., et al. Epilepsy and respiratory chain defects in children with mitochondrial encephalopathies. Neuropediatrics 2008, 39:8-13.
12. Lee Y.M., Kang H.C., Lee J.S., et al. Mitochondrial respiratory chain defects: Underlying etiology in various epileptic conditions. Epilepsia 2008, 49:685-690.
13. El Sabbagh S., Lebre A.S., Bahi-Buisson N., et al. Epileptic phenotypes in children with respiratory chain disorders. Epilepsia 2010, 51:1225-1235.
14. Waldbaum S., Patel M. Mitochondrial dysfunction and oxidative stress: A contributing link to acquired epilepsy?. J Bioenerg Biomembr 2010, 42:449-455.
15. Chang S.J., Yu B.C. Mitochondrial matters of the brain: Mitochondrial dysfunction and oxidative status in epilepsy. J Bioenerg Biomembr 2010, 42:457-459.
16. Finsterer J., Mahjoub S.Z. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol 2012, 8:71-79.
17. Bindoff L.A. Mitochondrial function and pathology in status epilepticus. Epilepsia 2001, 52(suppl 8):6-7.
18. Engelsen B.A., Tzoulis C., Karlsen B., et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008, 131:818-828.
19. Mayr J.A., Zimmermann F.A., Fauth C., et al. Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. Am J Hum Genet 2011, 89:792-2797.
20. Roshal D., Glosser D., Zangaladze A. Parieto-occipital lobe epilepsy caused by a POLG1 compound heterozygous A467T/W748S genotype. Epilepsy Behav 2011, 21:206-210.
21. Uusimaa J., Gowda V., McShane A., et al. Prospective study of POLG mutations presenting in children with intractable epilepsy: Prevalence and clinical features. Epilepsia 2013, 54:1002-1011.
22. Soini H.K., Molinanen J.S., Vilmi K., et al. Mitochondrial DNA variant m.15218 A>G in Finnish epilepsy patients who have maternal relatives with epilepsy, sensorineural hearing impairment or diabetes mellitus. BMC Med Genet 2013, 14:73.
23. Craig A.K., de Menezes S., Saneto R.P. Dravet syndrome: Patients with co-morbid SCN1A gene mutations and mitochondrial electron transport chain defects. Seizure 2012, 21:17-20.
24. Azakli H., Gurses C., Arikan M., et al. Whole mitochondrial DNA variations in hippocampal specimens and blood samples with high-throughput sequencing: A case of mesial temporal lobe epilepsy with hippocampal sclerosis. Gene 2013, 529:190-194.
25. Zhang X., Chen G., Lu Y., et al. Association of mitochondrial Letm1 with epileptic seizures. Cereb Cortex 2013, [Epub ahead of print].
26. Goldenthal M.J., Kuruvilla T., Damle S., et al. Non-invasive evaluation of buccal respiratory chain enzyme dysfunction in mitochondrial disease: Comparison with studies in muscle biopsy. Mol Genet Metab 2012, 105:457-462.
27. Khurana D., Goldenthal M., Valencia I., et al. Mitochondrial respiratory chain dysfunction in children with epilepsy. Epilepsia 2013, [Abstract].
28. Miles M.V., Miles L., Horn P.S., et al. Enzyme inducing antiepileptic drugs are associated with mitochondria proliferation and increased cytochrome c oxidase activity in muscle of children with epilepsy. Epilepsy Res 2012, 98:76-87.
29. Chuang Y.C., Chang A.Y., Lin J.W., et al. Mitochondrial dysfunction and ultrastructural damage in the hippocampus during kainic acid-induced status epilepticus in the rat. Epilepsia 2004, 45:1202-1209.
30. Kudin A.P., Kudina T.A., Seyfried J., et al. Seizure-dependent modulation of mitochondrial oxidative phosphorylation in rat hippocampus. Eur J Neurosci 2002, 15:1105-1114.
31. Gibbs J.E., Walker M.C., Cock H.R. Levetiracetam: Properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006, 47:464-478.
32. Sleven H., Gibbs J.E., Heales S., et al. Depletion of reduced glutathione precedes inactivation of mitochondrial enzymes following limbic status epilepticus in the rat hippocampus. Neurochem Int 2006, 48:75-82.
33. Folbergrová J., Ješina P., Haugvicová R., et al. Sustained deficiency of mitochondrial complex I activity during long periods of survival after seizures induced in immature rats by homocysteic acid. Neurochem Int 2010, 56:394-403.
34. Blümcke I., Zuschratter W., Schewe J.C., et al. Cellular pathology of hilar neurons in Ammon's horn sclerosis. J Comp Neurol 1999, 414:437-453.
35. Folbergrová J., Kunz W.S. Mitochondrial dysfunction in epilepsy. Mitochondrion 2012, 12:35-40.
36. Kunz W.S., Kudin A.P., Vielhaber S., et al. Mitochondrial complex I deficiency in the epileptic focus of patients with temporal lobe epilepsy. Ann Neurol 2000, 48:766-773.
37. Fujikawa D.G., Zhao S., Ke X., et al. Mild as well as severe insults produce necrotic, not apoptotic, cells: Evidence from 60-min seizures. Neurosci Lett 2010, 469:333-337.
38. Bengzon J., Kokaia Z., Elmer E., et al. Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures. Proc Natl Acad Sci U S A 1997, 94:10432-10437.
39. Venditti P., Di Stefano L., Di Meo S. Mitochondrial metabolism and oxygen species. Mitochondrion 2013, 13:71-82.
40. Martinc B., Grabnar I., Vovk T. The role of reactive species in epileptogenesis and influence of antiepileptic drug therapy on oxidative stress. Curr Neuropharmacol 2012, 10:328-343.
41. Rowley S., Patel M. Mitochondrial involvement and oxidative stress in temporal lobe epilepsy. Free Radic Biol Med 2013, 62:121-131.
42. Bruce A.J., Baudry M. Oxygen free radicals in rat limbic structures after kainate-induced seizures. Free Radic Biol Med 1995, 18:993-1002.
43. Gluck M.R., Jayatilleke E., Shaw S., et al. CNS oxidative stress associated with the kainic acid rodent model of experimental epilepsy. Epilepsy Res 2000, 39:63-71.
44. Liang L.P., Ho Y.S., Patel M. Mitochondrial superoxide production in kainate-induced hippocampal damage. Neuroscience 2000, 101:563-570.
45. Waldbaum S., Liang L.P., Patel M. Persistent impairment of mitochondrial tissue redox status during lithium-pilocarpine-induced epileptogenesis. J Neurochem 2010, 115:1172-1182.
46. Liang L.P., Waldbaum S., Rowley S., et al. Mitochondrial oxidative stress in SOD2 deficient mice: Attenuation by a lipophilic metalloporphyrin. Neurobiol Dis 2012, 45:1068-1076.
47. Mustafa A.G., Singh I.N., Wang J., et al. Mitochondrial protection after traumatic brain injury by scavenging lipid peroxyl radicals. J Neurochem 2010, 114:271-280.
48. Xu W., Chi L., Row B.W., et al. Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea. Neuroscience 2004, 126:313-323.
49. Gao J., Chi Z.F., Liu X.W., et al. Mitochondrial dysfunction and ultrastructural damage in the hippocampus of pilocarpine-induced epileptic rat. Neurosci Lett 2007, 411:152-157.
50. Folbergrová J., Ješina P., Nůsková H., et al. Antioxidant enzymes in cerebral cortex of immature rats following experimentally-induced seizures: Upregulation of mitochondrial MnSOD (SOD2). Int J Dev Neurosci 2013, 31:123-130.
51. Mueller S.G., Trabesinger A.H., Boesiger P., et al. Brain glutathione levels in patients with epilepsy measured by in vivo (1)H-MRS. Neurology 2001, 57:1422-1427.
52. Vielhaber S., Niessen H.G., Debska-Vielhaber G., et al. Subfield-specific loss of hippocampal N-acetyl aspartate in temporal lobe epilepsy. Epilepsia 2008, 49:40-50.
53. Kovac S., Domijan A.M., Walker M.C., et al. Prolonged seizure activity impairs mitochondrial bioenergetics and induces cell death. J Cell Sci 2011, 125:1796-1806.
54. Yuen A.W.C., Sander J.W. Impaired mitochondrial energy production: The basis for pharmacoresistance. Med Hypotheses 2011, 77:536-540.
55. Frantseva M.V., Velazquez J.L., Hwang P.A., et al. Free radical production correlates with cell death in an in vitro model of epilepsy. Eur J Neurosci 2000, 12:1431-1439.
56. Sudha K., Rao A.V., Rao A. Oxidative stress and antioxidants in epilepsy. Clin Chim Acta 2001, 303:19-24.
57. Berger I., Segal I., Shmueli D., et al. The effect of antiepileptic drugs on mitochondrial activity: A pilot study. J Child Neurol 2010, 25:541-545.
58. Gordon N. Alpers syndrome: Progressive neuronal degeneration of children with liver disease. Dev Med Child Neurol 2006, 48:1001-1003.
59. McFarland R., Hudson G., Taylor R.W., et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child 2008, 93:151-153.
60. Krahenbuhl S., Brandner S., Kleinle S., et al. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000, 20:346-348.
61. Stewart J.D., Horvath R., Baruffini E., et al. Polymerase y gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010, 52:1791-1796.
62. Luis P.B., Ruiter J.P., IJIst L., et al. Inhibition of 3-methylcrotonyl-CoA carboxylase explains the increased excretion of 3-hydroxyisovaleric acid in valproate-treated patients. J Inherit Metab Dis 2012, 35:443-449.
63. Price K.E., Pearce R.E., Garg U.C., et al. Effects of valproic acid on organic acid metabolism in children: A metabolic profiling study. Clin Pharmacol Ther 2011, 89:867-874.
64. Aires C.C., van Cruchten A., Ijlst L., et al. New insights on the mechanisms of valproate-induced hyperammonemia: Inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol 2011, 55:426-434.
65. Brion L., Gorostizaga A., Gomez N.V., et al. Valproic acid alters mitochondrial cholesterol transport in Y1 adrenocortical cells. Toxicol In Vitro 2011, 25:7-12.
66. Jafarian I., Eskandari M.R., Mashayekhi V., et al. Toxicity of valproic acid in isolated rat liver mitochondria. Toxicol Mech Methods 2013, 23:617-623.
67. Santos N.A., Medina W.S., Martins N.M., et al. Aromatic antiepileptic drugs and mitochondrial toxicity: Effects on mitochondria isolated from rat liver. Toxicol In Vitro 2008, 22:1143-1152.
68. Santos N.A., Medina W.S., Martins N.M., et al. Involvement of oxidative stress in the hepatotoxicity induced by aromatic antiepileptic drugs. Toxicol In Vitro 2008, 22:1820-1824.
69. Abelaira H.M., Reus G.Z., Ribeiro K.F., et al. Effects of acute and chronic treatment elicited by lamotrigine on behavior, energy metabolism, neurotrophins and signaling cascades in rats. Neurochem Int 2011, 59:1163-1174.
70. Andreux P.A., Houtkooper R.H., Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov 2013, 12:465-483.
71. Olszewska A., Szewczyk A. Mitochondria as a pharmacological target: Magnum overview. IUBMB Life 2013, 65:273-281.
72. Frier B.C., Williams B.D., Wright D.C. The effects of apelin treatment on skeletal muscle mitochondrial content. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1761-R1768.
73. Jones F.S., Jing J., Stonehouse A.H., et al. Caffeine stimulates cytochrome oxidase expression and activity in the striatum in a sexually dimorphic manner. Mol Pharmacol 2008, 74:673-684.
74. Menzies K.J., Robinson B.H., Hood D.A. Effect of thyroid hormone on mitochondrial properties and oxidative stress in cells from patients with mtDNA defects. Am J Physiol Cell Physiol 2009, 296:C355-C362.
75. Bastin J., Aubey F., Rotig A., et al. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components. Fundam Clin Pharmacol 2008, 19:511-519.
76. Viscomi C., Bottani E., Civiletto G., et al. In vivo correction of COX deficiency by activation of the AMP/PGC-1α axis. Cell Metab 2011, 14:80-90.
77. Bough K.J., Wetherington J., Hassel B., et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006, 60:223-235.
78. Jarrett S.G., Milder J.B., Liang L.P., et al. The ketogenic diet increases mitochondrial glutathione levels. J Neurochem 2008, 106:1044-1051.
79. Sullivan P.G., Rippy N.A., Dorenbos K., et al. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol 2004, 55:576-580.
80. Milder J., Patel M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res 2012, 100:295-303.
81. De Vivo D.C., Leckie M.P., Ferrendelli J.S., et al. Chronic ketosis and cerebral metabolism. Ann Neurol 1978, 3:331-337.
82. Balietti M., Giorgetti B., Di Stefano G., et al. A ketogenic diet increases succinic dehydrogenase (SDH) activity and recovers age-related decrease in numeric density of SDH-positive mitochondria in cerebellar Purkinje cells of late-adult rats. Micron 2010, 41:143-148.
83. 31P spectroscopic imaging at 4.1T. Epilepsia 1999, 40:703-707.
84. Kim Y.M., Vaidya V.V., Khusainov T., et al. Various indications for a modified Atkins diet in intractable childhood epilepsy. Brain Dev 2011, 34:620-624.
85. Pruss H., Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008, 82:219-222.